Multivitamin–Cisplatin Encapsulated Chitosan Nanoparticles Modulate DDX3X Expression in Cancer Cell Lines

Rajath Othayoth; Karishma Khatri; Ramya Gadicherla; Suseela Kodandapani; Mahendran Botlagunta

doi:10.26599/NBE.2023.9290008

Nano Biomedicine and Engineering 2023, 15(1): 74-85 https://doi.org/10.26599/NBE.2023.9290008

Research Article |

Open Access | Issue | Published: 09 May 2023

Multivitamin–Cisplatin Encapsulated Chitosan Nanoparticles Modulate DDX3X Expression in Cancer Cell Lines

Show Author's Information Hide Author's Information Rajath Othayoth^{¹^,²}, Karishma Khatri^{¹^,²}, Ramya Gadicherla^¹, Suseela Kodandapani^², Mahendran Botlagunta^{¹^,²^,³}(

)

1Department of Biotechnology, Koneru Lakshmaiah Education Foundation (KLEF), Guntur, India

2Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India

3School of Biosciences Engineering and Technology, VIT Bhopal University, Bhopal, India

Keywords:

atomic force microscope, cytotoxicity, transmission electron microscope, chemoprevention, NanoCisVital (NCV), Ki-67, DDX3X, cancer cell lines, cancer-related fatigue, nano-formulation

Cite this article:

Othayoth R, Khatri K, Gadicherla R, et al. Multivitamin–Cisplatin Encapsulated Chitosan Nanoparticles Modulate DDX3X Expression in Cancer Cell Lines. Nano Biomedicine and Engineering, 2023, 15(1): 74-85. https://doi.org/10.26599/NBE.2023.9290008

Download citation

EndNote(RIS)

BibTeX

1255

Views

178

Downloads

Citations

Crossref

N/A

WoS

Scopus

N/A

CSCD

Abstract Full text About this article

Abstract

Vitamin supplementation during chemotherapy has often been associated with lower recurrence and mortality rates in cancer patients. We had previously demonstrated that the multivitamin (C, D3, and B12)–cisplatin nanoparticle complex—NanoCisVital (NCV)—could alleviate chemotherapy-induced cancer fatigue. Chitosan is frequently used in functional nanomaterials to encapsulate drugs, because it is biodegradable, biocompatible, and non-toxic. The chitosan-based NCVs were prepared, and their physicochemical properties, size, and stability were evaluated before assessing their effect on cancer cell lines. The multivitamin mixture is packed in the core, and cisplatin is loaded at the periphery of the nanoparticle. This encapsulation facilitates the slow and sequential release of peripheral cisplatin and the core multivitamin combination. By increasing the amounts of vitamin and drug-encapsulated nanoparticles in breast and cervical cancer cell lines, the viable cell percentage was calculated. DDX3X promotes cancer cell proliferation, invasion, and metastasis, while Ki-67 promotes active cell proliferation in all cell types. DDX3X is elevated in several cancer types, and breast cancer cells express it abnormally. The Ki-67 protein is a biomarker of cell proliferation that is present throughout all active stages of the cell cycle but undetectable in the resting state. The expression of the DDX3X and Ki-67 genes is altered in NCV-treated cells. This study uses DDX3X and Ki-67 gene expression as a comparative measuring tool for the anti-cancer and cell proliferation effects of cisplatin and vitamins, respectively.

Full text

Abstract

Full text

Outline

About this article

Multivitamin–Cisplatin Encapsulated Chitosan Nanoparticles Modulate DDX3X Expression in Cancer Cell Lines

Show Author's information Hide Author's Information Rajath Othayoth^{¹^,²}, Karishma Khatri^{¹^,²}, Ramya Gadicherla^¹, Suseela Kodandapani^², Mahendran Botlagunta^{¹^,²^,³}(

)

1Department of Biotechnology, Koneru Lakshmaiah Education Foundation (KLEF), Guntur, India

2Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India

3School of Biosciences Engineering and Technology, VIT Bhopal University, Bhopal, India

Abstract

Keywords: atomic force microscope, cytotoxicity, transmission electron microscope, chemoprevention, NanoCisVital (NCV), Ki-67, DDX3X, cancer cell lines, cancer-related fatigue, nano-formulation

References(54)

[1]

D.P. Lawrence, B. Kupelnick, K. Miller, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. JNCI Monographs, 2004, 2004(32): 40−50. https://doi.org/10.1093/jncimonographs/lgh027

DOI Google Scholar

[2]

J.T. Hickok, J.A. Roscoe, G.R. Morrow, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer, 2005, 104(8): 1772−1778. https://doi.org/10.1002/cncr.21364

DOI Google Scholar

[3]

P.B. Jacobsen, D.M. Hann, L.M. Azzarello, et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. Journal of Pain and Symptom Management, 1999, 18(4): 233−242. https://doi.org/10.1016/s0885-3924(99)00082-2

DOI Google Scholar

[4]

K.M. Phillips, J. Pinilla-Ibarz, E. Sotomayor, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Supportive Care in Cancer, 2013, 21(4): 1097−1103. https://doi.org/10.1007/s00520-012-1630-5

DOI Google Scholar

[5]

P. Servaes, C. Verhagen, G. Bleijenberg. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. European Journal of Cancer, 2002, 38(1): 27−43. https://doi.org/10.1016/S0959-8049(01)00332-X

DOI Google Scholar

[6]

J.E. Bower, P.A. Ganz, K.A. Desmond, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 2000, 18(4): 743−753. https://doi.org/10.1200/JCO.2000.18.4.743

DOI Google Scholar

[7]

D. Cella, K. Davis, W. Breitbart, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 2001, 19(14): 3385−3391. https://doi.org/10.1200/JCO.2001.19.14.3385

DOI Google Scholar

[8]

J.E. Bower, P.A. Ganz, K.A. Desmond, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer, 2006, 106(4): 751−758. https://doi.org/10.1002/cncr.21671.PMID:16400678

DOI Google Scholar

[9]

P. Servaes, M.F. Gielissen, S. Verhagen, et al. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology, 2006, 16: 787−795. https://doi.org/10.1002/pon.1120

DOI Google Scholar

[10]

M. Olivares, E. Hertrampf, M.T. Capurro, et al. Prevalence of anemia in elderly subjects living at home: Role of micronutrient deficiency and inflammation. European Journal of Clinical Nutrition, 2000, 54(11): 834−839. https://doi.org/10.1038/sj.ejcn.1601099

DOI Google Scholar

[11]

P. Greenwald, D. Anderson, S.A. Nelson, et al. Clinical trials of vitamin and mineral supplements for cancer prevention. The American Journal of Clinical Nutrition, 2007, 85(1): 314S−317S. https://doi.org/10.1093/ajcn/85.1.314S

DOI Google Scholar

[12]

J.M. Gaziano, H.D. Sesso, W.G. Christen, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA, 2012, 308(18): 1871−1880. https://doi.org/10.1001/jama.2012.14641

DOI Google Scholar

[13]

C.H. Hennekens. Antioxidant vitamins and cancer. Patterns, 1994, 97(3a): 2S−4S. https://doi.org/10.1016/0002-9343(94)90291-7

DOI Google Scholar

[14]

D.J. Hunter, J.E. Manson, G.A. Colditz, et al. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. The New England Journal of Medicine, 1993, 329(4): 234−240. https://doi.org/10.1056/NEJM199307223290403

DOI Google Scholar

[15]

C.F. Garland, E.D. Gorham, S.B. Mohr, et al. Vitamin D for cancer prevention: global perspective. Annals of Epidemiology, 2009, 19(7): 468−483. https://doi.org/10.1016/j.annepidem.2009.03.021

DOI Google Scholar

[16]

R. Gniadecki, B. Gajkowska, M. Hansen. 1,25-Dihydroxyvitamin D3 stimulates the assembly of adherens junctions in keratinocytes: Involvement of protein kinase C. Endocrinology, 1997, 138(6): 2241−2248. https://doi.org/10.1210/endo.138.6.5156

DOI Google Scholar

[17]

N. Pendas-Franco, J.M. Gonzalez-Sancho, Y. Suarez, et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation; Research in Biological Diversity, 2007, 75(3): 193−207. https://doi.org/10.1111/j.1432-0436.2006.00131.x

DOI Google Scholar

[18]

A.C. Mamede, S.D. Tavares, A.M. Abrantes, et al. The role of vitamins in cancer: A review. Nutrition and Cancer, 2011, 63(4): 479−494. https://doi.org/10.1080/01635581.2011.539315

DOI Google Scholar

[19]

K.A. Conklin. Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects. Nutrition and Cancer, 2000, 37(1): 1−18. https://doi.org/10.1207/S15327914NC3701_1

DOI Google Scholar

[20]

J.D. Bauer, S. Capra. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Supportive Care in Cancer, 2005, 13(4): 270−274. https://doi.org/10.1007/s00520-004-0746-7

DOI Google Scholar

[21]

B.B. Aggarwal, S. Shishodia. Molecular targets of dietary agents for prevention and therapy of cancer. Biochemical Pharmacology, 2006, 71(10): 1397−1421. https://doi.org/10.1016/j.bcp.2006.02.009

DOI Google Scholar

[22]

L. Mu, S.S. Feng. PLGA/TPGS nano-particles for controlled release of paclitaxel: Effects of the emulsifier and drug loading ratio. Pharmaceutical Research, 2003, 20(11): 1864−1872. https://doi.org/10.1023/B:PHAM.0000003387.15428.42

DOI Google Scholar

[23]

K.Y. Win, S.S. Feng. In vitro and in vivo studies on vitamin E TPGS- emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials, 2006, 27(10): 2285−2291. https://doi.org/10.1016/j.biomaterials.2005.11.008

DOI Google Scholar

[24]

M. Chidambaram, R. Manavalan, K. Kathiresan. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. Journal of Pharmacy &Pharmaceutical Sciences, 2011, 14(1): 67−77. https://doi.org/10.18433/j30c7d

DOI Google Scholar

[25]

M.K. Yu, J. Park, S. Jon. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics, 2012, 2(1): 3−44. https://doi.org/10.7150/thno.3463

DOI Google Scholar

[26]

I. Cucinotto, L. Fiorillo, S. Gualtieri, et al. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: Nanodelivery reaches prime-time. Journal of Drug Delivery, 2013, 2013: 905091. https://doi.org/10.1155/2013/905091

DOI Google Scholar

[27]

B.R. Rizeq, N.N. Younes, K. Rasool, et al. Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles. International Journal of Molecular Sciences, 2019, 20(22): E5776. https://doi.org/10.3390/ijms20225776

DOI Google Scholar

[28]

M.P. Patel, R.R. Patel, J.K. Patel. Chitosan mediated targeted drug delivery system: A review. Journal of Pharmacy &Pharmaceutical Sciences, 2010, 13(4): 536−557. https://doi.org/10.18433/j3jc7c

DOI Google Scholar

[29]

L.T. Li, G. Jiang, Q. Chen, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review). Molecular Medicine Reports, 2015, 11(3): 1566−1572. https://doi.org/10.3892/mmr.2014.2914

DOI Google Scholar

[30]

J. Mo, H. Liang, C. Su, et al. DDX3X: structure, physiologic functions and cancer. Molecular Cancer, 2021, 20(1): 38. https://doi.org/10.1186/s12943-021-01325-7

DOI Google Scholar

[31]

M.R. Avadi, A.M. Sadeghi, N. Mohammadpour, et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine, 2010, 6(1): 58−63. https://doi.org/10.1016/j.nano.2009.04.007

DOI Google Scholar

[32]

M. Harvie. Nutritional supplements and cancer: potential benefits and proven harms. In: American Society of Clinical Oncology Educational Book. 2014: e478–e486.

DOI

[33]

F.F. Zhang, S.I. Barr, H. McNulty, et al. Health effects of vitamin and mineral supplements. BMJ, 2020, 369: m2511. https://doi.org/10.1136/bmj.m2511

DOI Google Scholar

[34]

L. Genç, H.M. Kutlu, G. Güney. Vitamin B12-loaded solid lipid nanoparticles as a drug carrier in cancer therapy. Pharmaceutical Development and Technology, 2015, 20(3): 337−344. https://doi.org/10.3109/10837450.2013.867447

DOI Google Scholar

[35]

M. Fidaleo, S. Tacconi, C. Sbarigia, et al. Current nanocarrier strategies improve vitamin B12 pharmacokinetics, ameliorate patients' lives, and reduce costs. Nanomaterials (Basel, Switzerland), 2021, 11(3): 743.

DOI

[36]

S. Amiri, M. Rezazadeh-Bari, M. Alizadeh-Khaledabad, et al. New formulation of vitamin C encapsulation by nanoliposomes: production and evaluation of particle size, stability and control release. Food Science and Biotechnology, 2019, 28(2): 423–432.

DOI

[37]

J. Baek, M. Ramasamy, N.C. Willis, et al. Encapsulation and controlled release of vitamin C in modified cellulose nanocrystal/chitosan nanocapsules. Current Research in Food Science, 2021, 4: 215−223. https://doi.org/10.1016/j.crfs.2021.03.010

DOI Google Scholar

[38]

E. Almouazen, S. Bourgeois, L.P. Jordheim, et al. Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation. Pharmaceutical Research, 2013, 30(4): 1137−1146. https://doi.org/10.1007/s11095-012-0949-4

DOI Google Scholar

[39]

A. Abbasi, Z. Emam-Djomeh, M.A. Mousavi, et al. Stability of vitamin D(3) encapsulated in nanoparticles of whey protein isolate. Food Chemistry, 2014, 143: 379−383. https://doi.org/10.1016/j.foodchem

DOI Google Scholar

[40]

P. Rajkumar, B.S. Mathew, S. Das, et al. Cisplatin concentrations in long and short duration infusion: Implications for the optimal time of radiation delivery. Journal of Clinical and Diagnostic Research, 2016, 10(7): XC01−XC04. https://doi.org/10.7860/JCDR/2016/18181.8126

DOI Google Scholar

[41]

S. Das, L. Jagan, R. Isiah, et al. Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery. Indian Journal of Pharmacology, 2011, 43(4): 409−413. https://doi.org/10.4103/0253-7613.83111

DOI Google Scholar

[42]

R. Othayoth, P. Mathi, K. Bheemanapally, et al. Characterization of vitamin-cisplatin-loaded chitosan nano-particles for chemoprevention and cancer fatigue. Journal of Microencapsulation, 2015, 32(6): 578−588. https://doi.org/10.3109/02652048.2015.1065921

DOI Google Scholar

[43]

A.M.D.C. Ferreira, R. Schneider Stock, F. Aiello. Design, synthesis, and preclinical testing of innovative anti-cancer compounds with a high level of selectivity of action and low toxicity. Frontiers in Molecular Biosciences, 2022, 9: 859821. https://doi.org/10.3389/fmolb.2022.859821

DOI Google Scholar

[44]

S. Senapati, A.K. Mahanta, S. Kumar, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduction and Targeted Therapy, 2018, 3: 7. https://doi.org/10.1038/s41392-017-0004-3

DOI Google Scholar

[45]

R. Singh, J.W. Lillard Jr. Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 2009, 86(3): 215−223. https://doi.org/10.1016/j.yexmp.2008.12.004

DOI Google Scholar

[46]

M. Anand, P. Sathyapriya, M. Maruthupandy, et al. Synthesis of chitosan nanoparticles by TPP and their potential mosquito larvicidal application. Frontiers in Laboratory Medicine, 2018, 2(2): 72−78. https://doi.org/10.1016/j.flm.2018.07.003

DOI Google Scholar

[47]

S. Dasari, P.B. Tchounwou. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology, 2014, 740: 364−378. https://doi.org/10.1016/j.ejphar.2014.07.025

DOI Google Scholar

[48]

A.L. Tardy, E. Pouteau, D. Marquez, et al. Vitamins and minerals for energy, fatigue and cognition: A narrative review of the biochemical and clinical evidence. Nutrients, 2020, 12(1): E228. https://doi.org/10.3390/nu12010228

DOI Google Scholar

[49]

C.B. Ambrosone, G.R. Zirpoli, A.D. Hutson, et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). Journal of Clinical Oncology, 2020, 38(8): 804−814. https://doi.org/10.1200/JCO.19.01203

DOI Google Scholar

[50]

J.E. Kim, H.S. Cho, H.S. Yang, et al. Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model. Immunobiology, 2012, 217(9): 873−881. https://doi.org/10.1016/j.imbio.2011.12.010

DOI Google Scholar

[51]

K. Singh, M. Bhori, Y.A. Kasu, et al. Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity. Saudi Pharmaceutical Journal, 2018, 26(2): 177−190. https://doi.org/10.1016/j.jsps.2017.12.013

DOI Google Scholar

[52]

M. Filippova, V. Filippov, V.M. Williams, et al. Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. BioMed Research International, 2014, 2014: 574659. https://doi.org/10.1155/2014/574659

DOI Google Scholar

[53]

P.S. Pramod, R. Shah, M. Jayakannan. Dual stimuli polysaccharide nanovesicles for conjugated and physically loaded doxorubicin delivery in breast cancer cells. Nanoscale, 2015, 7(15): 6636−6652. https://doi.org/10.1039/C5NR00799B

DOI Google Scholar

[54]

O. Shriwas, M. Priyadarshini, S.K. Samal, et al. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m⁶A-demethylation of FOXM1 and NANOG. Apoptosis, 2020, 25(3–4): 233–246.

DOI

About this article

Publication history

Acknowledgements

Rights and permissions

Publication history

Received: 15 June 2022

Revised: 23 January 2023

Accepted: 23 March 2023

Published: 09 May 2023

Issue date: March 2023

Copyright

Acknowledgements

Acknowledgement

We would like to express our sincere gratitude to Indo-American Cancer Research Foundation, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India for their support to conduct this study and Dr. Nandita Tanneru, Atal Incubation Centre, Centre for Cellular & Molecular Biology, Hyderabad, India in providing critical inputs and suggestions. This work was supported by DST-SERB, India under grant No. EMR/2017/001294.

Rights and permissions

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY) (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.